nuclear transport factor 2 pseudogene 7Genealiases: []
Q-omics provides the consensus-scored NUTF2P7 profile across patient tissues and cancer cell-line models. NUTF2P7 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NUTF2P7 is differentially expressed in 4, with the highest sampling consensus in KIRP. Additionally, NUTF2P7 RNA expression shows 8,020 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, KIRP, and BRCA as cancer lineages where NUTF2P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUTF2P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUTF2P7 survival associations across molecular data types. NUTF2P7 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUTF2P7 RNA expression–survival associations across cancer types. High NUTF2P7 expression shows unfavorable associations in KIRC, KICH and DLBC, but favorable associations in MESO, UCS and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NUTF2P7 RNA expression.
This table summarizes NUTF2P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for NUTF2P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUTF2P7 shows lower tumor expression in KIRC and higher tumor expression in KIRP, COAD and CHOL. The KIRP box plot shows higher NUTF2P7 RNA expression in tumor versus normal tissue (log2 FC = +0.111, t-test p = .002).
This table shows molecular features associated with NUTF2P7 in patient tissues and cancer cell lines. In patient samples, NUTF2P7 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
